Tihy M, Menzinger S, André R, et al. - Early diagnosis and management of cutaneous reactions to mRNA COVID-19 vaccines will benefit from a proper clinicopathological classification.

• A monocentric case series of 11 patients with cutaneous manifestations that were clinically and histologically characterized following COVID-19 vaccination was presented.

• Eleven cutaneous reactions to mRNA COVID-19 vaccines from BNT162b2 (n = 8) and mRNA-1273 (n = 3) were recorded from January to June 2021.

• The most common clinical presentation was an erythematous rash or purpura, and the most common histological finding was a drug reaction-like pattern.